Results 211 to 220 of about 6,329,421 (270)

ФоÑмÑÐ²Ð°Ð½Ð½Ñ ÑиклÑÑÐ½Ð¸Ñ Ð°Ð»Ð³Ð¾ÑиÑмÑв багаÑопаÑамеÑÑиÑного аналÑÐ·Ñ Ð¿ÑоÑеÑÑв ÑÑнкÑÑонÑÐ²Ð°Ð½Ð½Ñ Ð¼ÐµÑежÑ

, 2010
Шевченко, Н. Ю.; Национальный авиационный университет
openalex   +1 more source

Hemostatic net in cervical and facial surgeries: evidence from a systematic review and meta-analysis. [PDF]

Acta Cir Bras
Gonçalves FG, Silva LDD, Sampaio ECDF, Almeida AS, Terada BD, Malacarne GA, Friedmann ID, Moreira MR, Gemperli R, Camargo CP.   +9 more
europepmc   +1 more source

CD47 promotes mitogen‐activated protein kinase and epithelial‐to‐mesenchymal transition molecular programs to drive prometastatic phenotypes in non‐small cell lung cancer

Molecular Oncology, EarlyView.
Beyond its role in immune evasion, this study identified that CD47 drives tumor‐intrinsic signaling in non‐small cell lung cancer (NSCLC). Transcriptomic profiling and functional studies revealed that CD47 regulates cell adhesion, migration, and metastasis through an ERK–EMT signaling axis.
Asa P.Y. Lau, Lilian G. Zhai, Ryunosuke Hoshi, Zackary Rousseau, Abraam Zakhary, Yin Fang Wu, Rola M. Saleeb, Heyu Ni, Kelsie L. Thu   +8 more
wiley   +1 more source

Sugar-Sweetened Beverages Consumption among Koreans: Differences across Age Groups and Beverage Types. [PDF]

Prev Nutr Food Sci
Ganbat K, Kim BH, Song S.
europepmc   +1 more source

KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer

Molecular Oncology, EarlyView.
Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan, Veronika M Metzler, Simone de Brot, Corinne L Woodcock, Anna E Harris, Jennifer Lothion‐Roy, Emeli M Nilsson, Atara Ntekim, Michael S Toss, Jenny L Persson, Francesca Khani, Brian D Robinson, Lorraine J Gudas, Emad Rakha, David M Heery, Catrin S Rutland, Nigel P Mongan   +16 more
wiley   +1 more source

ÐаÑоби гаÑмонÑзаÑÑÑ Ð½Ð°Ð²ÑалÑÐ½Ð¸Ñ Ð¿ÑимÑÑÐµÐ½Ñ Ð² аÑпекÑÑ ÐµÐºÐ¾-виÑованнÑ

, 2016
M. Artenenko, O. Chepeljuk
openalex   +1 more source

ÐнедÑение CRM ÑиÑÑÐµÐ¼Ñ Ð² ÑÑÑболÑном клÑбе âТоÑноâ Ð´Ð»Ñ Ð¾Ð¿ÑимизаÑии взаимодейÑÑÐ²Ð¸Ñ Ñ Ð±Ð¾Ð»ÐµÐ»ÑÑиками

, 2018
Гасилин, Юрий
openalex   +1 more source

Triphenylmethyl Group as a Highly Diastereoselective <i>exo</i>,<i>endo</i>-Auxiliary in Double Diels-Alder Reactions with 2<i>H</i>-Pyran-2-ones. [PDF]

Molecules
Krivec M, Štirn Ž, Kočevar M, Kranjc K.   +3 more
europepmc   +1 more source

Heterozygous loss‐of‐function alleles associate the conserved 3′‐5′ exoribonuclease EXOSC10 with hypersensitivity to the anticancer drug 5‐fluorouracil

Molecular Oncology, EarlyView.
EXOSC10, an essential nuclear RNA exosome‐associated 3′‐5′ exoribonuclease, is inhibited by the anticancer drug 5‐fluorouracil (5‐FU), and EXOSC10 depletion increases 5‐FU sensitivity. The colon‐cancer variant EXOSC10S402T, located in a proteolysis motif, is stable and nuclear but nonfunctional in vivo.
Radhika Sain, Yann Le Page, Frédéric Percevault, Emmanuelle Becker, Luc Negroni, Almudena Fernandez, Marta Cantero, Diego Muñoz‐Santos, Lluís Montoliu, Cyrille Garnier, Michael Primig   +10 more
wiley   +1 more source

Combined Inhibition of TRPM4/NMDA Receptor Complex and Extrasynaptic NMDA Receptors Is Candidate Therapeutic Target for Suppression of Epileptic Seizures and Improvement of Cognitive Impairments. [PDF]

Pharmacol Res Perspect
Okada M, Okubo R, Oka T, Motomura E.
europepmc   +1 more source